Analysts Expect McKesson Co. (MCK) Will Post Earnings of $3.57 Per Share

Equities analysts expect McKesson Co. (NYSE:MCK) to report $3.57 earnings per share for the current fiscal quarter, Zacks Investment Research reports. Six analysts have provided estimates for McKesson’s earnings. The highest EPS estimate is $3.64 and the lowest is $3.54. McKesson reported earnings of $3.39 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 5.3%. The firm is expected to issue its next earnings results on Thursday, May 17th.

On average, analysts expect that McKesson will report full-year earnings of $12.71 per share for the current year, with EPS estimates ranging from $12.66 to $12.79. For the next fiscal year, analysts anticipate that the company will report earnings of $13.49 per share, with EPS estimates ranging from $13.11 to $13.74. Zacks’ EPS averages are a mean average based on a survey of sell-side analysts that follow McKesson.

How to Become a New Pot Stock Millionaire

McKesson (NYSE:MCK) last released its earnings results on Thursday, February 1st. The company reported $3.41 earnings per share for the quarter, topping the Zacks’ consensus estimate of $2.92 by $0.49. The firm had revenue of $53.62 billion for the quarter, compared to the consensus estimate of $51.98 billion. McKesson had a net margin of 2.34% and a return on equity of 22.98%. The company’s revenue was up 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.04 EPS.

MCK has been the topic of several recent analyst reports. Zacks Investment Research raised shares of McKesson from a “hold” rating to a “buy” rating and set a $177.00 price objective on the stock in a research report on Tuesday, December 26th. ValuEngine downgraded shares of McKesson from a “buy” rating to a “hold” rating in a research report on Sunday, December 31st. Evercore ISI initiated coverage on shares of McKesson in a research report on Thursday, January 4th. They set an “outperform” rating and a $179.00 price objective on the stock. Robert W. Baird reissued a “buy” rating and set a $200.00 price objective on shares of McKesson in a research report on Wednesday, January 17th. Finally, Needham & Company LLC increased their price objective on shares of McKesson from $173.00 to $180.00 and gave the company a “buy” rating in a research report on Tuesday, January 23rd. Two investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $176.74.

In other McKesson news, SVP Erin M. Lampert sold 1,413 shares of the company’s stock in a transaction dated Thursday, March 1st. The shares were sold at an average price of $149.38, for a total transaction of $211,073.94. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 1.20% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. Vulcan Value Partners LLC lifted its stake in shares of McKesson by 9.2% in the 4th quarter. Vulcan Value Partners LLC now owns 3,612,389 shares of the company’s stock worth $563,352,000 after purchasing an additional 305,492 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of McKesson by 6.2% in the 4th quarter. Bank of New York Mellon Corp now owns 2,697,323 shares of the company’s stock worth $420,648,000 after purchasing an additional 157,018 shares during the period. Pzena Investment Management LLC lifted its stake in shares of McKesson by 5.8% in the 4th quarter. Pzena Investment Management LLC now owns 2,600,401 shares of the company’s stock worth $405,533,000 after purchasing an additional 141,870 shares during the period. Alliancebernstein L.P. lifted its stake in shares of McKesson by 1.5% in the 4th quarter. Alliancebernstein L.P. now owns 2,450,313 shares of the company’s stock worth $382,126,000 after purchasing an additional 37,023 shares during the period. Finally, Geode Capital Management LLC lifted its stake in shares of McKesson by 0.5% in the 4th quarter. Geode Capital Management LLC now owns 2,270,865 shares of the company’s stock worth $353,418,000 after purchasing an additional 12,150 shares during the period. Institutional investors and hedge funds own 88.65% of the company’s stock.

MCK stock traded down $2.90 during trading on Friday, hitting $139.71. 2,012,983 shares of the stock traded hands, compared to its average volume of 1,787,881. McKesson has a 1 year low of $133.82 and a 1 year high of $178.86. The company has a market capitalization of $28,827.62, a price-to-earnings ratio of 12.03, a price-to-earnings-growth ratio of 1.25 and a beta of 1.32. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.61 and a current ratio of 1.07.

The business also recently announced a quarterly dividend, which was paid on Monday, April 2nd. Shareholders of record on Thursday, March 1st were paid a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a yield of 0.97%. The ex-dividend date was Wednesday, February 28th. McKesson’s dividend payout ratio is currently 11.71%.

ILLEGAL ACTIVITY NOTICE: “Analysts Expect McKesson Co. (MCK) Will Post Earnings of $3.57 Per Share” was originally reported by Ticker Report and is the property of of Ticker Report. If you are reading this article on another website, it was copied illegally and republished in violation of U.S. and international copyright legislation. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/3341510/analysts-expect-mckesson-co-mck-will-post-earnings-of-3-57-per-share.html.

About McKesson

McKesson Corporation is a healthcare supply chain management solutions, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare.

Get a free copy of the Zacks research report on McKesson (MCK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for McKesson (NYSE:MCK)

Receive News & Ratings for McKesson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for McKesson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Head-To-Head Survey: Weyco Group  vs. Talon International
Head-To-Head Survey: Weyco Group vs. Talon International
Contrasting Express  & Zumiez
Contrasting Express & Zumiez
LeMaitre Vascular  Reaches New 52-Week High and Low at $41.19
LeMaitre Vascular Reaches New 52-Week High and Low at $41.19
Broadcom Limited  Insider Sells $4,960,600.00 in Stock
Broadcom Limited Insider Sells $4,960,600.00 in Stock
John Deere  Stock Rating Reaffirmed by Royal Bank of Canada
John Deere Stock Rating Reaffirmed by Royal Bank of Canada
Quest Diagnostics  Upgraded to Buy by Zacks Investment Research
Quest Diagnostics Upgraded to Buy by Zacks Investment Research


Leave a Reply

© 2006-2018 Ticker Report. Google+.